Dual role of interleukin-33 in tumors.
10.11817/j.issn.1672-7347.2021.190678
- Author:
Qianqian LIU
1
;
Di LU
2
;
Jiahua HU
2
;
Junchao LIANG
3
;
Huoying CHEN
4
Author Information
1. Lingui College of Clinical Medicine, Guilin Medical University, Guilin Guangxi 541100. 570236803@qq.com.
2. Lingui College of Clinical Medicine, Guilin Medical University, Guilin Guangxi 541100.
3. Department of Traditional Chinese Medical Orthopedics, Eighth People's Hospital of Foshan, Foshan Guangdong 528200, China.
4. Lingui College of Clinical Medicine, Guilin Medical University, Guilin Guangxi 541100. fobufo@163.com.
- Publication Type:Journal Article
- Keywords:
interleukin-33;
suppression of tumorigenicity 2;
tumor;
tumor microenvironment
- MeSH:
Cytokines;
Humans;
Interleukin-33/genetics*;
MAP Kinase Signaling System;
NF-kappa B/metabolism*;
Neoplasms
- From:
Journal of Central South University(Medical Sciences)
2021;46(2):169-175
- CountryChina
- Language:English
-
Abstract:
Interleukin-33 (IL-33) is a new member of the IL-1 cytokine family which plays roles in the nucleus as a nuclear factor and is released by damaged or necrotic cells to act as a cytokine. It can be released via damaged or necrotic cells and functions as a cytokine. The released IL-33 activates the downstream NF-κB and MAPKs signaling pathways through the isomers of the specific receptor ST2 and the interleukin-1 receptor accessory protein (IL-1RAcP), resulting in danger signals and the activated multiple immune responses. IL-33 is abnormally expressed in various tumors and involves in tumorigenesis, development, and metastasis. Moreover, IL-33 can play both pro-tumor and anti-tumor roles in the same type of tumor.
